Joseph Bagnick, MD
Family Medicine · New Britain, PANPI 1932191558
Payments from drug & device makers
Across 162 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$434
- Pfizer$356
- Novo Nordisk$301
- GSK$180
- AbbVie$171
- Boehringer Ingelheim$142
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,59599%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $434 |
| Pfizer | 24 | $356 |
| Novo Nordisk | 13 | $301 |
| GSK | 10 | $180 |
| AbbVie(2 entities) | 9 | $171 |
| Boehringer Ingelheim | 9 | $142 |
| Lilly USA, LLC | 9 | $139 |
| Merck | 13 | $137 |
| Exact Sciences | 4 | $84 |
| Astellas Pharma US Inc | 5 | $80 |
| Novartis | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $50 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Boston Scientific | 2 | $43 |
| Johnson & Johnson | 3 | $40 |
| Amarin Pharma, Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Vertos Medical, Inc. | 2 | $37 |
| Medtronic(2 entities) | 2 | $30 |
| Amgen | 2 | $30 |
| Gilead | 2 | $29 |
| Assertio Therapeutics, Inc. | 2 | $25 |
| Kaleo, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,613 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $94,450 |
| TrulicityDulaglutide | 45 | $79,738 |
| JardianceEmpagliflozin | 58 | $79,126 |
| OzempicSemaglutide | 60 | $61,023 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $43,776 |
| FarxigaDapagliflozin Propanediol | 30 | $28,452 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $18,733 |
| XareltoRivaroxaban | 14 | $17,517 |
| JanuviaSitagliptin Phosphate | 12 | $16,397 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $11,875 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,404 |
| Valsartan | 194 | $8,399 |
| MyrbetriqMirabegron | 13 | $8,377 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $6,598 |
| Atorvastatin Calcium | 583 | $6,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $356 | $98,721138 claims |
| Lilly USA, LLCTrulicity | $139 | $79,73845 claims |
| Boehringer IngelheimJardiance | $142 | $79,12658 claims |
| Novo NordiskOzempic | $301 | $61,02360 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $52,18087 claims |
| MerckJanumet, Januvia | $137 | $35,13024 claims |
| AstraZenecaFarxiga, Brilinta | $434 | $33,33741 claims |
| Johnson & JohnsonXarelto | $40 | $17,51714 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $8,37713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $50 | $5,19811 claims |
| AbbVieSynthroid | $171 | $3,20360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in New Britain
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.